REMMO Injection 40 mg/vial contains Esomeprazole, a proton pump inhibitor (PPI) formulated as a MUPS (Multiple Unit Pellet System) preparation for intravenous administration. It is designed for rapid and effective inhibition of gastric acid secretion in conditions where oral therapy is not feasible or rapid acid suppression is required. Esomeprazole is the S-isomer of omeprazole and provides potent and long-lasting suppression of gastric acid by specifically inhibiting the H⁺/K⁺ ATPase enzyme in the gastric parietal cells.
REMMO Injection is particularly valuable in hospital settings for patients with severe acid-related disorders, critically ill patients at risk of stress-induced ulcers, and those unable to take oral medications. By reducing gastric acidity, REMMO Injection promotes ulcer healing, prevents gastrointestinal bleeding, and improves symptoms related to acid reflux.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Proton Pump Inhibitor (PPI)
REMMO Injection 40 mg is indicated for:
Peptic Ulcer Disease: Treatment of duodenal and gastric ulcers to promote healing and symptom relief.
Gastroesophageal Reflux Disease (GERD): Management of erosive esophagitis and long-term maintenance therapy to prevent relapse.
NSAID-Induced Ulcers: Prevention and treatment in patients at risk due to chronic NSAID therapy.
Stress Ulcer Prophylaxis: Critically ill patients in intensive care to reduce the risk of gastrointestinal bleeding.
Helicobacter pylori Eradication: In combination with appropriate antibiotics for H. pylori-positive ulcer disease.
Esomeprazole is a highly selective H⁺/K⁺ ATPase inhibitor that blocks the final step of gastric acid secretion. This inhibition is dose-dependent and long-lasting, providing effective suppression of both basal and stimulated gastric acid production. The MUPS formulation ensures controlled release and absorption, leading to improved bioavailability and consistent plasma concentrations, which are particularly beneficial in critically ill patients or those unable to take oral therapy.
Inhibits the proton pump of parietal cells, reducing gastric acid secretion.
Elevates gastric pH, creating a less acidic environment to promote ulcer healing.
Reduces acid-related tissue injury in the esophagus and stomach.
Standard Dose: 40 mg intravenous infusion once daily for adults.
Infusion: Administer over at least 3–5 minutes or as directed by a physician.
Treatment Duration: Depends on the indication; typically 4–8 weeks for ulcer healing.
Special Populations:
Renal Impairment: No dosage adjustment required.
Hepatic Impairment: Use caution in severe liver dysfunction; consider lower doses.
May affect absorption of drugs dependent on gastric pH (e.g., ketoconazole, atazanavir).
Can increase plasma concentrations of drugs metabolized by CYP2C19 (e.g., diazepam, phenytoin).
Care is advised when co-administered with clopidogrel; clinical monitoring may be necessary.
Hypersensitivity to esomeprazole, other PPIs, or any component of the formulation.
Use in patients with known severe liver impairment should be cautious.
REMMO Injection is generally well tolerated. Common adverse reactions include:
Headache
Nausea or vomiting
Diarrhea
Abdominal pain
Injection site reactions
Rarely, patients may experience dizziness, fatigue, or transient liver enzyme elevations.
Pregnancy: Should be used only if clearly needed; limited human data available.
Lactation: Excreted in breast milk in small amounts; weigh the benefits against potential risks before use.
Monitor liver function in patients receiving long-term therapy.
Consider magnesium monitoring for prolonged treatment due to rare hypomagnesemia.
Avoid abrupt discontinuation in patients requiring continuous acid suppression for severe reflux.
Store in a cool, dry place below 25°C. Protect from light. Keep out of reach of children.
Login Or Registerto submit your questions to seller
No none asked to seller yet